Eighty-three relapsed AML patients were enrolled in a retrospective study to evaluate the efficacy of sorafenib combined with other therapeutic strategies for AML with FLT3-ITD relapsed after allo-HSCT. This evidence concerns the gene FLT3 and acute myeloid leukemia.